Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 5 for:    Liberty 1
Previous Study | Return to List | Next Study

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03049735
Recruitment Status : Completed
First Posted : February 10, 2017
Last Update Posted : September 2, 2020
Sponsor:
Information provided by (Responsible Party):
Myovant Sciences GmbH

Brief Summary:
The purpose of this study is to determine the benefit of relugolix 40 milligrams (mg) once a day co-administered with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids.

Condition or disease Intervention/treatment Phase
Heavy Menstrual Bleeding Uterine Fibroid Drug: Relugolix Drug: Estradiol/norethindrone acetate Drug: Estradiol/norethindrone acetate placebo Drug: Relugolix placebo Phase 3

Detailed Description:

This study is an international phase 3 randomized, double-blind, placebo-controlled efficacy and safety study to evaluate 24 weeks of oral daily relugolix 40 mg co-administered with low-dose E2 and NETA (Group A) and 12 weeks of daily oral relugolix 40 mg alone followed by 12 weeks of daily oral relugolix 40 mg co-administered with low-dose E2 and NETA (Group B) compared with 24 weeks of placebo (Group C).

All participants completing the Week 24 visit, including women randomized to placebo, were offered the opportunity to enroll in an open-label extension study in which all eligible participants will receive relugolix co-administered with low-dose E2 and NETA. Participants who did not enroll into the extension study had a follow-up visit approximately 30 days after the end of treatment (that is, after the participant's last dose of study medication).

Safety will be assessed throughout the study by monitoring adverse events, vital signs, physical examinations, clinical laboratory tests, 12-lead electrocardiograms, and assessments of bone mineral density.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 388 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Actual Study Start Date : April 26, 2017
Actual Primary Completion Date : April 29, 2019
Actual Study Completion Date : August 24, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Relugolix plus E2/NETA (Group A)
Relugolix co-administered with E2/NETA for 24 weeks.
Drug: Relugolix
Relugolix (40 mg) tablet administered orally once daily.
Other Names:
  • TAK-385
  • MVT-601

Drug: Estradiol/norethindrone acetate
E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
Other Names:
  • E2/NETA
  • low-dose hormonal add-back

Experimental: Relugolix plus Delayed E2/NETA (Group B)
Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
Drug: Relugolix
Relugolix (40 mg) tablet administered orally once daily.
Other Names:
  • TAK-385
  • MVT-601

Drug: Estradiol/norethindrone acetate
E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
Other Names:
  • E2/NETA
  • low-dose hormonal add-back

Drug: Estradiol/norethindrone acetate placebo
E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.

Placebo Comparator: Placebo (Group C)
Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
Drug: Estradiol/norethindrone acetate placebo
E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.

Drug: Relugolix placebo
Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.




Primary Outcome Measures :
  1. Percentage Of Participants Who Achieve A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume Over The Last 35 Days Of Treatment [ Time Frame: From Baseline up to the last 35 days of treatment (up to 24 weeks) ]
    MBL volume is measured using the alkaline hematin method. For the primary analysis, the Relugolix plus E2/NETA group (Group A) will be compared with the Placebo group (Group C). Comparison of Relugolix plus Delayed E2/NETA group (Group A) with the Placebo group (Group C) will be a secondary analysis.


Secondary Outcome Measures :
  1. Percentage Of Participants With Amenorrhea (No Or Negligible Bleeding) Over The Last 35 Days Of Treatment [ Time Frame: From Baseline up to last 35 days of treatment (up to 24 weeks) ]
    Will be assessed using MBL volume measured using the alkaline hematin method and participant daily electronic diary (eDiary) data.

  2. Percent Change From Baseline At Week 24 In MBL Volume [ Time Frame: Baseline, Week 24 ]
    MBL volume is measured using the alkaline hematin method.

  3. Change From Baseline At Week 24 In Uterine Fibroid Symptom (UFS)-Quality of Life (QoL) Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL Questions 1, 2, and 5 [ Time Frame: Baseline, Week 24 ]
    Will be assessed with 3 questions (each with a 5-point scale ranging from 'Not at all' to 'A very great deal') related to menstrual bleeding and pelvic tightness/pressure.

  4. Percentage of Participants With A Hemoglobin Level ≤ 10.5 g/dL At Baseline Who Have An Increase In Hemoglobin > 2 g/dL From Baseline At Week 24 [ Time Frame: From Baseline up to Week 24 ]
    Blood samples will be collected from participants for hemoglobin measurements.

  5. Percentage Of Participants With A Maximum Numerical Rating Scale (NRS) Score ≤ 1 For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment [ Time Frame: From Baseline up to the last 35 days of treatment (up to 24 weeks) ]
    Uterine fibroid-associated pain will be assessed with a daily eDiary using an NRS score (11-point scale) in a subset of participants with a maximum NRS score ≥ 4 for pain associated with uterine fibroids during the last 35 days prior to randomization and at least 28 days with e-Diary entries of the last 35 days of treatment.

  6. Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume [ Time Frame: Baseline, Week 24 ]
    Volume of the primary uterine fibroid will be measured by transvaginal or transabdominal ultrasound.

  7. Percent Change From Baseline At Week 24 In Uterine Volume [ Time Frame: Baseline, Week 24 ]
    Volume of the uterus will be measured by transvaginal or transabdominal ultrasound.

  8. Time To MBL Response [ Time Frame: From Baseline through Week 24 ]
    Defined as the time to achieve an MBL volume of < 80 mL and a ≥ 50% reduction from baseline MBL volume as measured by the alkaline hematin method.

  9. Change From Baseline At Week 24 In Impact On QoL, Assessed Using The UFS-QoL Questionnaire [ Time Frame: Baseline, Week 24 ]
  10. Change From Baseline At Week 24 In Symptoms Assessed Using The Patient Global Assessment (PGA) Questionnaire [ Time Frame: Baseline, Week 24 ]
    The PGA for symptoms is a 1-item questionnaire designed to assess participant's impression of the severity of their symptoms related to uterine fibroids.

  11. Change From Baseline At Week 24 In Function Assessed Using The PGA Questionnaire [ Time Frame: Baseline, Week 24 ]
    The PGA for function is a 1-item questionnaire designed to assess participant's impression of how their symptoms related to uterine fibroids affected their usual activities.

  12. Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 - L4) [ Time Frame: Baseline, Week 12 ]
    Assessed by a dual-energy X-ray absorptiometry (DXA) scan.

  13. Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 - L4), Total Hip, And Femoral Neck [ Time Frame: Baseline, Week 24 ]
    Assessed by a DXA scan.

  14. Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 12 [ Time Frame: From Baseline through Week 12 ]
  15. Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 24 [ Time Frame: From Baseline through Week 24 ]
  16. Predose Trough Concentrations Of Relugolix And NETA In The Relugolix Plus E2/NETA Group At Week 24 [ Time Frame: Week 24 ]
    Blood samples for determination of relugolix and NETA plasma concentrations will be collected for measurements.

  17. Predose Trough Concentrations Of E2 In The Relugolix Plus E2/NETA Group At Week 24 [ Time Frame: Week 24 ]
    Blood samples for determination of E2 plasma concentrations will be collected for measurements.

  18. Change In Serum Concentrations Of Luteinizing Hormone, Follicle-stimulating Hormone, Estradiol, And Progesterone [ Time Frame: Up to 24 weeks ]
    Blood samples will be collected from participants for hormonal measurements.

  19. Percent Change From Baseline At Weeks 4, 8, 12, 16, And 20 In MBL Volume [ Time Frame: Baseline to Weeks 4, 8, 12, 16, and 20 ]
  20. Time To Achieve An MBL Volume Of < 80 mL And At Least A 50% Reduction From Baseline MBL Volume [ Time Frame: From Baseline through Week 24 ]
    MBL volume is measured using the alkaline hematin method.

  21. Percentage Of Participants In The Relugolix Plus E2/NETA Group Versus The Placebo Group Who Achieve An MBL Volume Of < 80 mL And At Least A 50% Reduction From Baseline MBL Volume By Visit [ Time Frame: From Baseline through Week 24 ]
  22. Sustained Amenorrhea Rate (No Or Negligible Bleeding) By Visit [ Time Frame: From Baseline through Week 24 ]
  23. Time To Achieving Sustained Amenorrhea (No Or Negligible Bleeding) [ Time Frame: From Baseline through Week 24 ]
  24. Time To Achieving Amenorrhea (No Or Negligible Bleeding) [ Time Frame: From Baseline through Week 24 ]
  25. Percentage Of Participants With A Hemoglobin Concentration Below The Lower Limit Of Normal At Baseline Who Achieve An Increase Of ≥ 1 g/dL From Baseline At Week 24 [ Time Frame: From Baseline through Week 24 ]
  26. Change From Baseline At Week 24 In Hemoglobin For Participants With A Hemoglobin Concentration ≤ 10.5 g/dL At Baseline [ Time Frame: Baseline, Week 24 ]
  27. Change From Baseline At Week 24 In The UFS-QoL Symptom Severity Scale Score [ Time Frame: Baseline, Week 24 ]
  28. Change From Baseline At Week 24 In The UFS-QoL Activities Scale Score [ Time Frame: Baseline, Week 24 ]
  29. Change From Baseline At Week 24 In The UFS-QoL Revised Activities Scale Score [ Time Frame: Baseline, Week 24 ]
  30. Proportion Of Responders Who Achieve A Meaningful Increase Of At Least 20 Points From Baseline At Week 24 In UFS-QoL Revised Activities Scale Score [ Time Frame: From Baseline through Week 24 ]
  31. Proportion Of Responders Who Achieve A Meaningful Reduction Of At Least 20 Points From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score [ Time Frame: From Baseline through Week 24 ]
  32. Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Physical Activities Based On UFS-QoL Question 11 [ Time Frame: Baseline, Week 24 ]
  33. Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Social Activities Based On UFS-QoL Question 20 [ Time Frame: Baseline, Week 24 ]
  34. Change From Baseline At Week 24 In Embarrassment Caused By Uterine Fibroids Based On UFS-QoL Question 29 [ Time Frame: Baseline, Week 24 ]
  35. Participants Achieving Improvement From Baseline In PGA For UFS From Baseline At Week 24 [ Time Frame: From Baseline through Week 24 ]
  36. Participants Achieving Improvement From Baseline In PGA For Uterine Fibroid-related Function From Baseline At Week 24 [ Time Frame: From Baseline through Week 24 ]
  37. Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Physical Activities [ Time Frame: Baseline, Week 24 ]
  38. Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Social And Leisure Activities [ Time Frame: Baseline, Week 24 ]
  39. Participants Who Achieve A Maximum NRS Score For Pain Associated With Uterine Fibroids Over The Last 35 Days Of Treatment [ Time Frame: From Baseline up to the last 35 days of treatment (up to 24 weeks) ]
    The maximum NRS score should be at least a 30% reduction from baseline in the subset of participants with a maximum pain score ≥ 4 during the 35 days prior to randomization.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Premenopausal female aged 18 to 50 years old (inclusive) on the day of signing and dating the informed consent form.
  2. Has regularly occurring menstrual periods of ≤ 14 days duration with a cycle of 21 to 38 days from the start of 1 menstrual period until the start of the next, by participant history for at least 3 months prior to the first screening visit.
  3. Has a diagnosis of uterine fibroids that is confirmed by a transvaginal and/or transabdominal ultrasound performed during the screening period.
  4. Has heavy menstrual bleeding associated with uterine fibroids as evidenced by an MBL of ≥ 160 milliliter (mL) during 1 cycle or ≥ 80 mL per cycle for 2 menstrual cycles as measured by the alkaline hematin method during the screening period.

Key Exclusion Criteria:

  1. Has transvaginal and/or transabdominal ultrasound during the screening period demonstrating pathology other than uterine fibroids that could be responsible for or contributing to the patient's heavy menstrual bleeding.
  2. Has known rapidly enlarging uterine fibroids in the opinion of the investigator.
  3. Has a weight that exceeds the weight limit of the DXA scanner or has a condition that precludes an adequate DXA measurement at the lumbar spine and proximal femur.
  4. Has a history of or currently has osteoporosis, or other metabolic bone disease, hyperparathyroidism, hyperprolactinemia, hyperthyroidism, anorexia nervosa, or low traumatic (from the standing position) or atraumatic fracture (toe, finger, skull, face and ankle fractures are allowed). A history of successfully treated hyperparathyroidism, hyperprolactinemia, or hyperthyroidism is allowed if the participant's bone mineral density is within normal limits.
  5. Has a history of the use of bisphosphonates, calcitonin, calcitriol, ipriflavone, teriparatide, denosumab, or any medication other than calcium and vitamin D preparations to treat bone mineral density loss.
  6. Has been a participant in an investigational drug or device study within the 1 month prior to the first screening visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03049735


Locations
Hide Hide 110 study locations
Layout table for location information
United States, Alabama
Andalusia
Andalusia, Alabama, United States, 36420
Mobile
Mobile, Alabama, United States, 36608
United States, Arkansas
Little Rock
Little Rock, Arkansas, United States, 72205
United States, California
La Mesa
La Mesa, California, United States, 91942
Lomita
Lomita, California, United States, 90717
Norwalk
Norwalk, California, United States, 90650
Oceanside
Oceanside, California, United States, 92056
San Diego
San Diego, California, United States, 92108
San Diego
San Diego, California, United States, 92111
United States, Colorado
Denver
Denver, Colorado, United States, 80209
United States, Florida
Aventura
Aventura, Florida, United States, 33180
Brandon
Brandon, Florida, United States, 33510
Clearwater
Clearwater, Florida, United States, 33759
Clermont
Clermont, Florida, United States, 34711
Fort Myers
Fort Myers, Florida, United States, 33912
Hialeah
Hialeah, Florida, United States, 33012
Hialeah
Hialeah, Florida, United States, 33016
Jacksonville
Jacksonville, Florida, United States, 32207
Lauderdale Lakes
Lauderdale Lakes, Florida, United States, 33319
Margate
Margate, Florida, United States, 33063
Miami
Miami, Florida, United States, 33155
Miami
Miami, Florida, United States, 33165
Miami
Miami, Florida, United States, 33176
Orlando
Orlando, Florida, United States, 32806
Orlando
Orlando, Florida, United States, 32808
Palm Harbor
Palm Harbor, Florida, United States, 34684
South Miami
South Miami, Florida, United States, 33143
Tampa
Tampa, Florida, United States, 33613
West Palm Beach
West Palm Beach, Florida, United States, 33409
Weston
Weston, Florida, United States, 33327
United States, Georgia
Atlanta
Atlanta, Georgia, United States, 30342
Atlanta
Atlanta, Georgia, United States, 49074
Augusta
Augusta, Georgia, United States, 30912
College Park
College Park, Georgia, United States, 30349
Richland
Richland, Georgia, United States, 99352
United States, Illinois
Oakbrook
Oakbrook Terrace, Illinois, United States, 60523
United States, Indiana
Lafayette
Lafayette, Indiana, United States, 47905
United States, Louisiana
Covington
Covington, Louisiana, United States, 70433
Shreveport
Shreveport, Louisiana, United States, 71118
United States, Missouri
St. Louis
Saint Louis, Missouri, United States, 63141
United States, Nebraska
Lincoln
Lincoln, Nebraska, United States, 68510
Omaha
Omaha, Nebraska, United States, 68124
United States, Nevada
Las Vegas
Las Vegas, Nevada, United States, 89106
Las Vegas
Las Vegas, Nevada, United States, 89128
United States, New Jersey
Lawrenceville
Lawrenceville, New Jersey, United States, 08648
United States, New Mexico
Albuquerque
Albuquerque, New Mexico, United States, 87109
United States, New York
Williamsville
Williamsville, New York, United States, 14221
United States, North Carolina
Durham
Durham, North Carolina, United States, 27713
Morehead City
Morehead City, North Carolina, United States, 28557
Raleigh
Raleigh, North Carolina, United States, 27612
United States, North Dakota
Bismarck
Bismarck, North Dakota, United States, 58501
Fargo
Fargo, North Dakota, United States, 58103
Minot
Minot, North Dakota, United States, 58701
United States, Ohio
Cincinnati
Cincinnati, Ohio, United States, 45219
Cincinnati
Cincinnati, Ohio, United States, 45267
Dayton
Dayton, Ohio, United States, 45409
Englewood
Englewood, Ohio, United States, 45322
United States, Pennsylvania
Philadelphia
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
Bluffton
Bluffton, South Carolina, United States, 29910
Charleston
Charleston, South Carolina, United States, 29406
Columbia
Columbia, South Carolina, United States, 29201
Greenville
Greenville, South Carolina, United States, 29605
United States, Tennessee
Chattanooga
Chattanooga, Tennessee, United States, 37404
Memphis
Memphis, Tennessee, United States, 38119
Memphis
Memphis, Tennessee, United States, 38120
United States, Texas
Fort Worth
Fort Worth, Texas, United States, 76104
Houston
Houston, Texas, United States, 77054
Houston
Houston, Texas, United States, 77074
Irving
Irving, Texas, United States, 75062
San Antonio
San Antonio, Texas, United States, 78229
Sugar Land
Sugar Land, Texas, United States, 77479
Webster
Webster, Texas, United States, 77598
United States, Utah
Salt Lake City
Salt Lake City, Utah, United States, 84107
Salt Lake City
Salt Lake City, Utah, United States, 84124
United States, Virginia
Norfolk
Norfolk, Virginia, United States, 23507
United States, Washington
Seattle
Seattle, Washington, United States, 98105
Brazil
Curitiba
Curitiba, Brazil, 80430-160
Porto Alegre
Porto Alegre, Brazil, 90510-040
Ribeirao Preto
Ribeirão Preto, Brazil, 14049-900
Santo Andre
Santo André, Brazil, 09190-510
Sao Paulo
São Paulo, Brazil, 01317-000
Italy
Bologna
Bologna, Italy, 40138
Catanzaro
Catanzaro, Italy, 88100
Fiernze
Firenze, Italy, 50134
Genova
Genova, Italy, 16132
Milano
Milano, Italy, 20132
Modena
Modena, Italy, 41124
Monserrato
Monserrato, Italy, 09042
Napoli
Napoli, Italy, 80131
Roma
Roma, Italy, 00161
Roma
Roma, Italy, 00168
Siena
Siena, Italy, 53100
Torino
Torino, Italy, 10126
Poland
Katowice
Katowice, Poland, 40-123
Lublin
Lublin, Poland, 20-093
Lublin
Lublin, Poland, 20-632
Poznan
Poznań, Poland, 60-535
Szczecin
Szczecin, Poland, 71-270
Warszawa
Warszawa, Poland, 02-201
Warszawa
Warszawa, Poland, 02-507
Lodz
Łódź, Poland, 90-602
Lodz
Łódź, Poland, 91-308
South Africa
Durban
Durban, South Africa, 4052
Durban
Durban, South Africa, 4126
Port Elizabeth
Port Elizabeth, South Africa, 6001
Roodepoort
Roodepoort, South Africa, 1724
United Kingdom
Birmingham
Birmingham, United Kingdom, B15 2TG
Isleworth
Isleworth, United Kingdom, TW7 6AF
London
London, United Kingdom, SE5 9NY
Nottingham
Nottingham, United Kingdom, NG7 2FT
Sponsors and Collaborators
Myovant Sciences GmbH
Investigators
Layout table for investigator information
Study Director: Myovant Medical Monitor Myovant Sciences
Layout table for additonal information
Responsible Party: Myovant Sciences GmbH
ClinicalTrials.gov Identifier: NCT03049735    
Other Study ID Numbers: MVT-601-3001
2016-003727-27 ( EudraCT Number )
First Posted: February 10, 2017    Key Record Dates
Last Update Posted: September 2, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Myovant Sciences GmbH:
Uterine Fibroid
Heavy Menstrual Bleeding
Menstrual Blood Volume
Additional relevant MeSH terms:
Layout table for MeSH terms
Leiomyoma
Myofibroma
Menorrhagia
Hemorrhage
Pathologic Processes
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Connective Tissue
Connective Tissue Diseases
Uterine Hemorrhage
Uterine Diseases
Menstruation Disturbances
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Norethindrone
Norethindrone Acetate
Estradiol
Polyestradiol phosphate
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female
Contraceptives, Oral, Synthetic
Contraceptives, Oral